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Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong 
Objectives: To determine the significance of Lipoprotein (a) (Lp(a)) as a risk factor for atherosclerotic lower limb 
peripheral vascular disease (PVD), and its relationship to other demographic and biochemical variables and disease pattern 
and severity. 
Design: Prospective case-control study. 
Material and methods: Demographic and biochemical risk factors, lipoprotein fractions and Lp(a) were measured in 
200 patients with PVD and 200 age- and sex-matched control subjects. Lp(a) levels were correlated with traditional risk 
factors and clinical and vascular laboratory disease parameters. 
Results: Patients with PVD have a higher incidence of smoking, hypertension, and diabetes mellitus; and had significantly 
higher levels of serum cholesterol, triglycerides, LDL, VLDL, apolipoprotein B, fasting glucose, fibrinogen, plasminogen, 
haematocrit, white cell and platelet counts; but lower levels of HDL and apolipoprotein A1. Fasting Lp (a) concentration 
is an independent risk factor for PVD and is significantly higher in the patients (median =26.1 mg/dl [4.8-195], mean = 
36.5+_32.6mg/dl) than in controls (median=18.2 mg/dl [5.4-216], mean=27.2 +_28.1mg/dl; p<O.O001). In patients 
with PVD, Lp(a) correlated positively with plasma LDL, cholesterol, fibrinogen, renal disease, and apolipoprotein K 
Fasting levels of>24 mg/dl incurred a two-fold increase in risk of PVD. Patients with a higher Lp(a) have a significantly 
higher incidence of resting pain and ulcerations, and regression analysis confirmed smoking and Lp(a) level to be associated 
with the SVS category of disease severity. 
Conclusions: Lipoprotein (a) is a significant independent risk factor for PVD. Lp(a) levels correlated with LDL, 
cholesterol, fibrinogen, apolipoprotein B and disease severity. An elevated Lp(a) level may be associated with more severe 
forms of PVD. 
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Introduction 
Lipoprotein (a) (Lp(a)) is a genetically determined, 
cholesterol~rich plasma lipoprotein which has been 
shown to be a risk factor for premature atherosclerosis. 
Reports on the association of atherosclerotic diseases 
and Lp(a) were largely based on research in patients 
with myocardial infarction and stroke. Studies on peri- 
pheral arterial diseases were uncommon, 1-5 and de- 
tailed inter-relationships between Lp(a) and  other 
atherogenic variables and lower limb disease para- 
meters have not been described. This study aimed 
to determine (1) if elevated Lp(a) is associated with 
atherosclerotic peripheral arterial disease (PVD), (2) 
whether Lp(a) is an independent risk factor for PVD 
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with regard to the other traditional risk factors, (3) the 
prevalence and relative risk of PVD patients with high 
Lp(a) in a Chinese population, and (4) the relationship 
and significance of a high Lp(a) level with the severity 
and pattern of PVD. 
Material and Methods 
A prospective case-control study was conducted be- 
tween August 1993 and February 1996 at the Division 
of Vascular Surgery, Department of Surgery, The Uni- 
versity of Hong Kong, Queen Mary Hospital. Chinese 
patients aged 40-80 years who presented consecutively 
with symptoms of lower limb atherosclerotic peri- 
pheral arterial occlusive disease (PVD), confirmed by 
clinical symptoms and non-invasive vascular laborat- 
ory studies, were recruited. Patients who had un- 
salvageable limbs, known hypercoagulable states, 
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renal failure, malignancy, or pregnancy were excluded 
from the study. 
A control group of subjects was recruited from 
healthy volunteers and from patients in general clinics 
with non-related minor surgical problems. The subjects 
were selected such that they were exactly matched for 
age and sex to the patient group. All controls had 
a physical examination to exclude the possibility of 
asymptomatic PVD. Those who had known metabolic, 
liver and other diseases affecting lipids and lipoprotein 
metabolism, and those on lipid-lowering medications, 
were excluded. A sample size of 200 in each group 
was chosen for a 90% power to detect a difference of 
10 mg/dl  between the patient and control means for 
Lp(a). 
Patient data and risk factor assessment 
A total of 200 patients and 200 age- and sex-matched 
controls were recruited into the study. Each group 
consisted of 129 men and 71 women, with a mean 
age of 67 years. All subjects were interviewed and 
examined by a vascular surgeon and the following 
parameters were recordecl: age, sex, body weight, 
smoking habits (number and duration), history of 
hypertension (diastolic blood pressure >90 mmHg), 
systolic and diastolic blood pressure, diabetes mellitus, 
history of cardiac, cerebrovascular, renal diseases, and 
family history. The peripheral pulses of the subjects 
were palpated and the presence or absence of disease 
confirmed. Blood was collected by venepuncture from 
patients and controls after a 12 h fast. Haematological 
parameters were measured by standard methods 
(haemoglobin, white cell and platelet count, haem- 
atocrit, prothrombin time and activated partial throm- 
boplastin time and fibrinogen). Plasminogen activity 
was measured by colorimetric assay of streptokinase- 
plasminogen i teraction on a synthetic hromogenic 
substrate. 6 Biochemical risk factors were also de- 
termined, including fasting glucose, creatinine, total 
cholesterol, triglycerides, and the lipid fractions (LDL, 
VLDL, HDL). Apolipoprotein B, apolipoprotein A1, 
and Lp(a) were separately determined by antiserum- 
antibody reactions using immunoturbidometric assay 
(Incstar corporation, Stillwater, MN, U.S.A.) .  7 
Non-invasive vascular laboratory investigations and 
classification of disease 
All patients were investigated in the non-invasive 
vascular laboratory. A full set of lower limb Doppler 
Table 1. Patient characteristics (n=200). 
Disease distribution SVS/ISCVS category 8 
Aortoiliac 46 1 Mild claudication 23 
Fernoropopliteal 98 2 Moderate claudication 43 
Distal 22 3 Severe claudication 33 
Combined 34 4 Rest pain 27 
5 Tissue loss 74 
SVS/ISCVS=Society of Vascular Surgery/International Society of 
Cardiovascular Surgery. 
assessments, including segmental b ood pressure and 
waveforms, ankle-brachial index measurements, and 
an exercise treadmill stress test (5 min, 2 mph at 12 
degrees incline), were performed. The disease severity 
is graded according to the standards for reports dealing 
with lower extremity ischaemia, using clinical and 
vascular !aboratory criteria, specified by the Ad Hoc 
Committee on Reporting Standards, Society of Vas- 
cular Surgery/International Society for Cardiovascular 
Surgery (SVS/ISCVS). s
Statistical methods 
All results were expressed as mean+ S.D. where ap- 
propriate. Demographic and biochemical data of 
patient and control groups wer e compared using uni- 
variate methods by the Student's t-test (independent 
samples, two-tailed) and the Chi-squared statistic. Be- 
cause of the skewed frequency distributions of the 
Lp(a) concentrations, the differences between Lp(a) in 
patients and controls were compared using Student's 
t-test after logarithmic transformation of the Lp(a) 
values. Significant univariate variables were then 
entered into multivariate analysis using a forward 
stepwise logistic regression model. Lp(a) levels were 
also correlated with other known factors associated 
with atherosclerosis u ing Pearson's correlation co- 
efficient. A baseline value for Lp(a) in this population 
group was established using logistic regression of the 
log Lp(a) values. The relationships between risk factors 
and disease pattern and severity were obtained by 
multiple regression analysis. 
Results 
Patient characteristics 
The characteristics, disease pattern and severity of the 
200 patients are listed in Table 1. The disease severity 
is listed according to SVS/ISCVS criteria. 8 Eighty-three 
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Table 2. Demographic and biochemical parameters of patients and controls. 
Parameter Controls Patients p-value 
(mean ± S.D. (n = 200) (n = 200) 
Smoking 
Diabetes 
Hypertension 
Cholesterol (mmol/1) 
Triglycerides (mmol/1) 
HDL cholesterol (mmol/1) 
LDL (mmol/1) 
VLDL (mmol/1) 
Apolipoprotein B (g/dl) 
Apolipoprotein A1 (rag/d1) 
Lipoprotein (a) (mg/dl) 
Fasting lucose (mmol/1) 
Fibrinogen (g/l) 
Plasminogen (%) 
Haematocrit 
White cell count ( x 10-9/1) 
Platelets ( x 10 9/1) 
Prothrombhl time (s) 
APTT (s) 
59 138 <0.0001 
15 86 <0.0001 
54 132 <0.0001 
5.41 + 1.29 5.80 ± 1.38 <0.005 
1.41 + 0.86 1.88 + 1.04 <0.0001 
1.25 + 0.40 1.11 + 0.45 <0.001 
3.42 + 1.07 3.91 ± 1.37 <0.0001 
0.67 ± 0.44 0.88 ± 0.54 <0.0001 
107 ± 27 122 + 30 <0.0001 
142 ± 31 133 + 27 <0.005 
27.2 ± 28.1 36.5 ± 32.6 <0.0001" 
18.2 (5.4-216)# 26.1 (4.8-195)t 
5.74 ± 1.49 7.12 _+ 2.94 <0.0001 
3.10 ± 0.71 3.70 ± 1.02 <0.0001 
95 ± 19 104 ± 18 <0.0001 
0.42 ± 0.04 0.40 ± 0.07 <0.001 
6.92 ± 1.78 9.02 ± 3.00 <0.0001 
217 i 64 260 ± 95 <0.0001 
10.5±1.0 10.6±2.1 NS 
29.5±17.7 29.6±7.6 NS 
Values are given as mean + standard eviation. 
NS =not significant (p>0.05). 
* Using Student's t-test on log Lp(a) levels. 
f Median (range). 
patients had PVD symptoms of the left leg, 75 had right 
leg disease, and 42 patients had bilateral problems. 
Risk factors 
The demographic data, the haematological nd bio- 
chemical risk factors of the patient and control groups, 
and the results of univariate statistic analysis are listed 
in Table 2. Patients with PVD have a higher incidence 
of smoking, hypertension, and diabetes mellitus, and 
had significantly higher levels of serum cholesterol, 
triglycerides, LDL, VLDL, apolipoprotein B, fasting 
glucose, fibrinogen, plasminogen, haematocrit, white 
cell and platelet counts; but lower levels of HDL and 
apol ipoprotein A1. 
The distribution of Lp(a) levels in both  the patients 
and controls were skewed (Fig. 1). Fasting Lp(a) con- 
centrations were significantly higher in the patient 
group (med ian=26.1mg/d l  [4.8-195], mean=36.5+ 
32.6mg/dl )  than in controls (med ian=18.2mg/d l  
[5.4-216], mean = 27.2 + 28.1 mg/d l ;  p<0.0001, Fig. 1). 
Lp(a) levels were slightly higher in male patients 
(median =27.2 mg/d l ,  mean =38.1 +33.9 mg/d l )  than 
in female patients (med ian=23.5mg/d l ,  mean= 
33.7+30.7mg/dl ) ,  but the difference was not stat- 
istically significant. 
Multivariate analysis by stepwise logistic regression 
showed that Lp(a) concentration is a significant risk 
factor for PVD, independent of the other significant 
risk factors: smoking, hypertension, diabetes mellitus, 
glucose level, plasminogen, and platelet count (Table 
3). 
In patients with PVD, Lp(a) correlated positively 
with plasma LDL, cholesterol, fibrinogen, renal dis- 
ease, apolipoprotein B, and the category of disease. In 
the control subjects, Lp(a) correlated positively with 
LDL and ApoB, but inversely with body weight (Table 
4). There is no relationship of Lp(a) levels with the 
patients' diabetic status, smoking habits, or the pres- 
ence or absence of hypertension, cardiac disease, or 
stroke. Plasminogen activity showed a wide range in 
both patients (18-137%)and controls (17-135%) and 
had no correlation with Lp(a). Only three patients 
and four control subjects showed significant hypo- 
plasminogenaemia (<50%). 
Table 3. Independent risk factors for PVD, stepwise logistic re- 
gression results. 
Significant risk factor B p-value R 
Lipoprotein (a) 0.01 <0.05 0.07 
Plasminogen 0.02 <0.005 0.12 
Glucose 0.19 <0.05 0.07 
Smoking 0.87 <0.001 0.28 
Hypertension 0.91 <0.001 0.18 
Diabetes mellitus 1.59 <0.001 0.17 
Platelet count 0.01 <0.05 0.06 
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Fig. 1. Fasting Lipoprotein (a) concentrations in 200 patients with atherosclerotic peripheral arterial occlusive disease and 200 age- and 
sex-matched controls (M:139, F:71). 
Relative risk estimation 
Using logistic regression of the logarithmic trans- 
formed Lp(a) values, a Lp(a) level of 24 mg/d l  was 
determined to be the reference cut-off value dif- 
ferentiating between disease and control groups in our 
study populat ion.  A total of 36% of the control subjects 
had Lp(a) levels exceeding 24 mg/d l ,  whereas 53% of 
the patients had elevated Lp(a) concentrations, giving 
a relative risk of PVD at 2.0. The comparat ive odds 
ratios of the other significant r isk factors are shown 
in Table 5. 
Table 4. Pearson's correlation of Lipoprotein (a) with other risk 
factors in patients and controls. 
Risk factor Pearson's p-value 
coefficient (r) 
Patients 
LDL 0.26 <0.0001 
Cholesterol 0.24 <0.001 
Fibrinogen 0.23 <0.005 
Renal disease* 0.21 <0.005 
Apolipoprotein B 0.16 <0.05 
SVS disease category 0.18 <0.05 
Controls 
LDL 0.21 <0.005 
Apolipoprotein B 0.18 <0.05 
Body weight - 0.16 <0.05 
* Creatinine >250 ~mol/1. 
LDL = Low density lipoprotein. 
Lipoprotein (a) and disease 
Multiple regression analysis showed that smoking 
and Lp(a) were the only significant variables to be 
associated with the SVS/ISCVS category of disease at 
presentation. Patients with elevated Lp(a) (n=106) 
also have a higher incidence of resting pain (48% vs. 
29%, p<0.005), and ulcerations (34% vs. 21%, p<0.05), 
but a lower incidence of claudication (71% vs. 83%, 
p<0.05) compared with patients with Lp(a) levels less 
than 24 mg/d l  (n =94). Patients who presented with 
critical ischaemia (SVS/ISCVS category 4-6, n =101) 
were found to have a significantly higher Lp(a) con- 
centration (median 31 .1mg/d l ,  [5.4-216], mean= 
41.2 _+ 36 .1mg/d l )  than patients who presented with 
claudication alone (SVS/ISCVS category 1-3, n=99;  
median 21 .7mg/d l ,  [5.4-114.8], mean=31.7± 
28.1 mg/d l ;  p<0.005). 
Table 5. Relative risks of peripheral arterial atherosclerosis (200 
patients). 
Significant risk Upper limit % elevated ~ Odds p-value 
factors in patients ratio 
Lipoprotein (a) 24 mg/dl 53 2.00 <0.001 
Plasminogen 100% 61 2.69 <0.001 
Fasting glucose 6.6 mmol/1 40 6.28 <0.001 
Platelet count 260 x 10-9/1 39 2.98 <0.001 
Smoking - 69 5.25 <0.001 
Hypertension - 61 5.04 <0.001 
Diabetes mellitus - 43 9.23 <0.001 
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Of the 200 patients, 106 underwent surgery. These 
consisted of 75 arterial bypasses, 11 primary endo- 
vascular procedures, eight endarterectomies, 10 ampu- 
tations and two sympathectomies. Patients who 
required an operation also had a significantly higher 
level of Lp(a) (median 30.0mg/dl [5.4-216], mean 
40.6+35.7mg/cll, n=106) than patients treated con- 
servatively (median 22.0mg/dl [5.4-110.4], mean= 
32.0+28.3mg/dl, n=94; p<0.05). Lp(a) level had no 
relationship with the patient's ex or the distribution 
of disease. 
Discussion 
Lipoprotein (a) is a heterogenous macromolecule first 
identified in 1963. During the 1980s elevated levels of 
Lp(a) were found to be associated with early myo- 
cardial infarction, 9'1° coronary artery disease, n and 
stroke. 12 Recently, similar studies into the lipid profiles 
in patients with peripheral vascular disease have found 
evidence that Lp(a) is an independent risk factor for 
peripheral atherosclerosis. 1-3 Several theories have 
been proposed to explain this association. Reports of 
accumulation of Lp(a)in atherosclerotic lesions in the 
aorta and coronary arteries ~3 suggested that Lp(a) can 
interact with macrophages to stimulate athero- 
genesis. 14 Lp(a) also has a strong homology with the 
fibrinolytic enzyme plasminogen, and their genes are 
adjacent to each other on chromosome 6.15.Therefore 
Lp(a) may also exert its effect in atherogenesis via 
the coagulation pathway by competitively binding to 
plasminogen receptors and inhibiting fibrinolysis. ~6 
We have shown in this prospective case-control 
study that Lp(a) is an independent risk factor for 
peripheral vascular disease. The control population in 
the present study is selected from a group of healthy 
individuals who are exactly age- and sex-matched to
the patients. This design was considered essential, as 
there is evidence to suggest a significant relationship 
of Lp(a) levels with age and sex. 17'~s The distribution 
of Lp(a) in the study population is skewed, consistent 
with other reports. ~'~° The mean and median values of 
Lp(a) in our control population also correlated well 
with normal values in previous maller scale data on 
younger healthy Chinese subjects, where a mean Lp(a) 
level of 22.9 mg/dl  has been described. 19
The risk factors for atherosclerosis in the Chinese 
population had not been extensively studied, although 
a high level of serum Lp(a) has been correlated with 
a higher risk of stroke and myocardial infarction. 2°'21 
A detailed, controlled study into all possible predictors 
of PVD in this ethnical population has not been ab 
tempted before. This study showed a high prevalence 
of demographic risk factors in the patients, particularly 
smoking (69%) and hypertension (66%). It is also note- 
worthy that a high percentage (43%) of the patients 
were diabetic. These three traditional risk factors were 
also the most powerful factors on relative risk analysis; 
diabetes increases the risk of peripheral therosclerosis 
by a factor of nine, and smoking and hypertension each 
incurred a five-fold increase in risk. In the presence 
of hyperlipidaemia, these risk factors may further 
potentiate atherogenesis. For practical reasons the 
patients and controls were not matched for smoking 
and diabetes, but despite this difference Lp(a) was 
still demonstrated as a significant risk factor. In the 
presence of multiple known demographic (smoking, 
hypertension, diabetes), lipid, and biochemical risk 
factors for PVD, Lp(a) on multivariate logistic re- 
gression is the strongest predictor for PVD among 
the standard variables in lipid profile (cholesterol, 
triglycerides, LDL, VLDL, Apolipoprotein A1 and B). 
This indicated that an elevated level of Lp(a) is an 
important risk factor for PVD. 
The process leading to arterial occlusion in athero- 
sclerosis often involved an episode of thrombosis, 
but haemostatic variables have always been under- 
emphasised. In the present study the patients were 
found to have significantly higher fibrinogen levels, 
and white cell and platelet counts. Elevated fibrinogen 
and white cell levels in patients with atherosclerotic 
diseases had been previously reported, 1 and could 
account for hastened thrombosis. The presence of local 
infection in PVD patients with toe ulcers and gangrene 
can also explain a raised white cell count. Although 
reduced platelet survival had been reported, a high 
platelet level was generally not recognised as a risk 
factor for atherosclerosis. 
There has been no literature on the relationship of 
Lp(a) and the pattern and severity of atherosclerotic 
lower limb peripheral vascular disease, the majority 
primarily directed upon coronary atherosclerosis, per- 
haps because of the difficulty of accurately assessing 
the arteries of the lower limb. In an attempt to relate 
Lp(a) levels to disease pattern and severity, the patients 
in the present study were categorised by symptoms 
and objective vascular laboratory criteria which has 
been standardised. We found no relationship between 
Lp(a) and the level of disease. Regression analysis 
suggested a positive relationship of Lp(a) with the 
disease severity as rated according to the SVS/ISCVS 
category. Patients with high Lp(a) also tend to suffer 
more from resting pain and tissue loss, and are more 
likely to require operative intervention. The possible 
predictive value of this observation and its significance 
and implication in disease progression may justify 
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treatment of raised Lp(a) levels. A full interpretation 
Would require a more detailed analysis into disease 
pattern and progression in the future. At present it 
seems that clinical manifestations of critical forms of 
peripheral ischaemia re associated with a higher level 
of Lp(a). 
Factors that have been reported to affect Lp(a) levels 
include diabetes, renal failure, and defects in lipid 
metabolism. Liver disease and lipid lowering med- 
ications were excluded from this study. The re- 
lationship of Lp(a) and diabetes is unclear. Although 
some reports had shown an association, 2 we did not 
find any significant correlation of Lp(a) levels with 
diabetes or fasting blood glucose concentration. Our 
patients with diabetes did have lower levels of Lp(a), 
and patients with cardiac disease and stroke higher 
levels of Lp(a), but the difference did not reach stat- 
istical significance. There was a correlation of Lp(a) 
with serum creatinine, but only three patients had a 
creatinine level in excess of 250 gmol/1. 
Lp(a) levels in our patients correlated with fib- 
rinogen, cholesterol, LDL and ApoB, in agreement with 
previous research. 1'17'22 As a result, the contribution of 
these factors could be eliminated from the risk factor 
logistic regression analysis. It has also 'been shown 
that the relative risk of myocardial infarction increases 
significantly in patients with high LDL. 23 Maher et al. 
have demonstrated recently that reduction of elevated 
LDL cholesterol in patients with elevated Lp(a) could 
result in a reduction of relative cardiovascular risk. 24 
Lp(a) levels are very resistant o standard lipid-low- 
ering therapy, with the exception of niacin. 2~ If the 
association of Lp(a) and LDL could be further sub- 
stantiated in future, a more feasible method of treat- 
ment could be applied to patients with high Lp(a) and 
LDL, with a goal of risk reduction in both coronary 
and peripheral vascular disease. 
The gene for Apo(a) is located on chromosome 6 
and is adjacent o the gene for plasminogen. Apo(a) 
also has a high structural homology to plasminogen. 
Reduced plasminogen activity from competitive 
binding of Lp(a) to plasminogen receptors has been 
proposed as a risk factor for thrombogenesis. 26 Plas- 
minogen activity is also measured in both our control 
and patient groups, and the result was distributed 
across a wide range of values. Only a small number 
of subjects expressed hypoplasminogenaemia. Thein- 
cidental finding of a higher mean plasminogen level 
in patients than controls is paradoxical and probably 
of no clinical significance. 
There has been no consensus on the cut-off reference 
point between normal and abnormal concentrations 
of Lp(a), owing to the variations between populations 
and the lack of standardisation f the technique of the 
method of analysis. Recently, with the introduction of 
an automated immunoturbidometric assay, 7 an ac- 
curate, non-isotopic method of measuring Lp(a) can 
be used in the clinical laboratory for integrating Lp(a) 
screening into risk factor determination and analysis 
for peripheral vascular disease. This method of Lp(a) 
assay adopted in the present study had previously 
been proven to be comparable to ELISA analysis. 7 
Using logistic regression analysis, a level of 24 mg/ 
dl was chosen as a reference for our local Chinese 
population. This level is also comparable to values 
adopted by some Western studies. I° An individual 
with an elevated Lp(a) is twice as likely to develop 
PVD. Lp(a) levels may vary greatly between ethnic 
groups, and most population studies provided ata for 
Caucasians only. 27 S imi la r  information on the Chinese 
population is limited. Our data could provide some 
insight into the risk factors for atherogenesis in Asians. 
This study has shown that the Lp(a) levels in the 
Chinese is comparable to Caucasians. It is a common 
belief that the incidence of atherosclerotic disease is 
less common in Asians. A difference in Lp(a) value 
cannot explain the relatively infrequent occurrence of 
atherosclerotic PVD in the Chinese. The prevalence of 
strong traditional risk factors of smoking, diabetes, 
and hypertension is also in agreement with data from 
the West. It is likely that the occurrence of PVD in the 
Chinese is a multi-factorial ction, possibly genetically 
predisposed, and modified by environmental factors. 
We conclude that Lp(a) is a significant independent 
risk factor for PVD. A Lp(a) level of 24mg/dl  or 
greater is found in 53% of a group of Chinese patients 
in the seventh decade with PVD and is associated 
with a two-fold increase in relative risk. Lp(a) levels 
correlated with LDL, cholesterol, fibrinogen, apolipo- 
protein B and disease severity. An elevated Lp(a) level 
may be associated with a more severe form of PVD. 
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